ADAKVEO

Brand name authorized in: Austria Brazil Finland France Ireland Lithuania Poland United Kingdom United States

Active ingredients

The drug ADAKVEO contains one active pharmaceutical ingredient (API):

1 Crizanlizumab
UNII L7451S9126 - CRIZANLIZUMAB

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1.

Read about Crizanlizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Crizanlizumab
B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX01

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Structured product labeling (SPL/PLR)
US

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
BR
Câmara de Regulação do Mercado de Medicamentos
Identifier(s): 526520070096307
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 181522
FR
Base de données publique des médicaments
Identifier(s): 62004984
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 396539
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1091344
PL
Rejestru Produktów Leczniczych
Identifier(s): 100446201
US
FDA, National Drug Code
Identifier(s): 0078-0883